First in vivo proof-of-concept of your compound's impact on hepatic VLDL-TG production.
This technique is extremely useful for compounds designed to treat type 2 diabetes cardiovascular complications and/or dislipidemia due to excessive hepatic lipogenesis.
Key benefits
- Impact of your compound on hepatic VLDL-TG production, an index of hepatic lipogenesis: determine whether increased fasting or fed circulating triglyceride levels come from increased hepatic production or from reduced clearance.
- In vivo insights into your compound's efficacy on cardiovascular parameters: VLDL-TG production by the liver is involved in the abnormal lipoprotein profile.
- Suitable for large-scale screening purposes in vivo (20-30 compounds/week).
Add-on studies
- Lipoprotein turnover measurement to determine your compound's in vivo efficacy on lipoprotein metabolism.
References
This technique has been developed and validated internally at Physiogenex. For reasons of confidentiality, references are available only on request, from contact@physiogenex.com
